Abstract: A needle-holding cartridge for cosmetic treatments includes a casing with a first part, intended to be rested on a zone of the body of a patient in which a cosmetic treatment has to be performed, and a second part intended to be inserted into and locked in an appropriate seat obtained at an end of a device for cosmetic treatments, inside the first part of the casing a support element being arranged that can slide inside the casing; to the support element a single needle or a plurality of needles is fixed that can protrude from the casing through an opening placed at a first end of the casing, the support element being provided with a rod-shaped appendage, a portion of which protrudes from the casing through a hole obtained at a second end of the casing, opposite the first end; the needle-holding cartridge further includes a first ring-shaped sealing element that surrounds the appendage and is inserted into a seat obtained at the second end of the casing, and a sheath-shaped second sealing element placed on sa

Abstract: Transdermal drug delivery devices are described herein such as a microneedle array patch, to be placed on the skin for transdermal delivery of a medicament. The transdermal drug delivery device for delivery of a bioactive agent through mammalian skin comprises an array of microneedles and a means to actuate the microneedles, wherein the actuation means actuates the microneedles separately.

Abstract: A patch-type drug infusion device includes a control structure provided with multiple first fastening portions and first electrical contacts; and an infusion structure including a case, a power supply, a flexible circuit board, and an elastic conductor, and provided with multiple second electrical contacts and second fastening portions that cooperate with the first fastening portions. The first fastening portions and the second fastening portions are fastened, the first electrical contacts connect with the corresponding second electrical contacts, making the structure more compact and improving the space utilization rate inside the infusion structure.

Abstract: Provided is a butterfly needle assembly, including: a flexible member having a central region with a first side member and a second side member collectively providing a generally flat bottom, the central region having a middle area; an adhesive dressing disposed upon the generally flat bottom, the adhesive dressing protected by a removable cover; a needle hub disposed within the central region, the needle hub receiving a flexible tubing line generally parallel to the generally flat bottom and providing a needle extending generally normal to the generally flat bottom from the middle area of the central region, the needle extending for a first length; a removable needle cover initially disposed about the needle, the removable needle cover structured and arranged to removably engage with the needle hub; and a closing system structured and arranged to close the first side member and the second side member of the flexible member about the needle. A method of making a butterfly needle assembly is also provided.

Abstract: A microneedle array has a plurality of microneedles, said microneedles being supported by a substrate. In order to improve the properties of the microneedle array, the substrate is in the form of a grid structure or comprises a grid structure.

Abstract: Disclosed are a heat-resistant implantable polymer microneedle and a preparation method therefor and an application thereof. The microneedle comprises a needle tip, a needle body, and a base, wherein the needle tip comprises a homogeneous system formed by mixing a biodegradable macromolecular material which has a glass transition temperature of 35-65° C. and is difficultly soluble in water and a macromolecular material having a glass transition temperature higher than that of the biodegradable macromolecular material. The microneedle has good heat resistance and puncture property.

Abstract: The present application discloses a coated microneedle with a multilayer structure, including a base, a needle tip on the base, and a functional coating. The functional coating includes a content including a water-soluble polymer material and an active ingredient, and a sustained-release layer wrapping the content. The sustained-release layer covers the needle tip. The coated microneedle can prevent a drug-containing matrix from being quickly dissolved and dispersed, prevent the active ingredient from exuding along with tissues at an action site, and increase the drug intake. The present application further discloses a method for preparing the coated microneedle and a microneedle patch including the coated microneedle.

Abstract: Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

Abstract: Various intraoral gastrointestinal access devices, systems, and methods are disclosed herein to deliver substance directly to a target gastrointestinal tract site of a user while bypassing other portions of the gastrointestinal tract. The intraoral gastrointestinal access devices can be anchored within a mouth of a user and are generally concealed when not in use. The intraoral gastrointestinal access devices can include a port that is docked in the mouth when not in use and positioned outside the mouth to receive substance from a delivery device with a reservoir of the substance.

Abstract: The present invention relates to a syringe and medical kit, which allow for doses of epinephrine of 0.15 mg or 0.15 mL, 0.3 mg or 0.3 mL, and 0.5 mg or 0.5 mL, the most commonly prescribed doses which are utilized today in treating anaphylaxis or other allergic reactions. Currently, existing syringes may include many markings of ten or more dosages. Although these prior art syringes are useful, it is difficult to use them for a patient who must quickly identify a correct dose level among many other marks. The above problem can be addressed by a syringe design which has only a few dosage markings, which correspond to commonly used standard dosages for children and adults. When used with a standard concentration of 1:1000 epinephrine solution, such a device can rapidly provide a known quantity of medicine to a patient who is in urgent need of it.

Abstract: Methods and apparatuses for treating inflammatory diseases by neurostimulation in patients who have failed to adequately respond or have become intolerant to a drug therapy (such as a TNF inhibitor and/or a JAK inhibitor).

Abstract: Syringes are described herein. A syringe includes a syringe body, a first plunger, a biasing member, and a priming indicator. The syringe body defines a syringe cavity, a syringe port, and an indicator window, wherein the syringe port is in fluid communication with the syringe cavity. The first plunger comprises a first plunger shaft extending from the first plunger, the first plunger disposed within the syringe cavity and defining a first chamber in the syringe cavity, wherein the first chamber is in fluid communication with the syringe port. The biasing member couples to the first plunger shaft, wherein the biasing member urges the first plunger from an unprimed position to a primed position toward the syringe port. The priming indicator presents the first indicator portion through the indicator window in the unprimed position and presents the second indicator portion through the indicator window in the primed position.

Abstract: Disclosed herein are exemplary medical devices for delivery of compositions to a target site. A disclosed medical device may comprise a delivery device comprising a delivery device comprising a handle, a composition delivery container and its plunger, an insertion tube, a dual lumen catheter comprising an exit port and optionally, an end structure, and fluid connections therefor, components for moving one or more catheters or for compressing one or more catheters. Methods of treatment and diagnosis using a disclosed delivery device, compositions for such methods and kits and systems are also disclosed.

Abstract: Plasma delivery tips of medical-grade plasma generating devices are configured to exclude potential contaminants while operating within body cavities. In some embodiments, delivery tips are provided with an antechamber, which is optionally filled by pressure of ionizing gas to prevent contamination. Some embodiments are provided with one or more interior and/or exterior valves configured to prevent proximal ingress of contamination to the longitudinal position of the discharge electrode, or at all into the gas delivery lumen. In some embodiments, an expandable distal section of the plasma delivery tip acts as a valve which seals when closed, and when open expands to generate an inflated antechamber into which plasma is delivered.

Abstract: A therapeutic agent delivery system includes a therapeutic agent delivery assembly carried by a housing. The therapeutic agent delivery assembly includes a chamber including a first passageway, a therapeutic agent carried in the first passageway, and a needle in communication with the first passageway. The therapeutic agent delivery assembly is translatable relative to the housing from a stowed configuration to a deployed configuration. The therapeutic agent delivery assembly is also translatable relative to the housing from the deployed configuration to a retracted configuration. The system further includes a user input that is actuatable to translate the therapeutic agent delivery assembly from the stowed configuration to the deployed configuration. The system further includes a retraction mechanism that is actuatable to translate the therapeutic agent delivery assembly from the deployed configuration to the retracted configuration.

Abstract: An intraluminal system for aspirating biological material from a lumen of a patient includes a disposable intraluminal device having a proximal portion and a distal portion. The system includes a disposable pump configured to aspirate the biological material from the lumen of the patient. The disposable pump is coupled to the proximal portion of the intraluminal device. The disposable pump comprises a pump chassis that houses: an inlet port configured to sealably attach to the proximal portion of the intraluminal device; an outlet port configured to expel the aspirated biological from the pump; and a flow controller configured to adjust a fluid flow through the pump, wherein the pump chassis is sized and shaped to be manually supported by a user.

Abstract: An introducer sheath for the insertion of a medical device into a blood vessel having an expandable sheath. The sheath has a length, a thickness, and proximal and distal ends. The expandable sheath has a frame extending longitudinally between the proximal and the distal ends, and having an exterior surface and an interior surface that forms an interior lumen along the length of the frame. The frame is configured to achieve an expanded state and a contracted state, the expanded state forming an expanded cross-section in the lumen for passing a medical device therethrough. The frame has a smooth coating about the exterior surface and protrusions extending into the lumen along the interior surface. The introducer sheath can be introduced into a patient in the contracted state, with the distal end of the introducer sheath prevented from moving in the proximal direction by an abutment against a dilator end surface.

Abstract: A silicone implant is fixed onto the thyroid cartilage and the implant has a guide channel extending therethrough. The placement allows fixation to the cartilage by blade portions on opposite sides of the implant, with the guide channel being positioned in front of the muscles to be treated. The implant enables safe, accurate, and repeatable injections into internal laryngeal muscles under local anesthesia, and simplifies surgical access, increases accuracy, and reduces risks associated with traditional techniques.

Abstract: A gelatin-based (e.g., gelatin methacryloyl (GelMA)) patch is disclosed with an array of microneedles (MNs) for minimally invasive sampling of bodily fluids such as interstitial fluid (ISF). The properties of the patch can be tuned by altering the concentration of the GelMA prepolymer and the crosslinking time. The GelMA-based MN patch demonstrated efficient extraction of ISF. Furthermore, in experimental testing, the patch efficiently and quantitatively detects glucose and vancomycin in ISF in an in vivo study. This minimally invasive approach of extracting ISF with a GelMA microneedle enables to detection and analysis of target molecules from patients. The target molecules captured in the patch may be released and analyzed to detect the presence of and/or concentration of target molecules. In other embodiments, the patch itself may be analyzed directly to detect the presence of and/or concentration of target molecules.

Abstract: The present invention provides an implantable electrostimulation-based drug delivery system incorporating microneedle-based drug delivery module connecting with a wirelessly-controlled electrostimulation module such that under a small input power generated by magnetic coupling between a transmission antenna and a harvester of the wirelessly-controlled electrostimulation module, one or more substances stored in the microneedles can be released to tissues of a target site while no subsequent removal of the system from the target site is required as the system is entirely biodegradable and bioresorbable in vivo after a sufficient period of time.